This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Minoxidil
A K+ channel-opening vasodilator originally approved for severe hypertension that grew hair as a side effect, then got repurposed twice —…
Aliases (7)
Overview
What is Minoxidil?
Minoxidil is a piperidinopyrimidine vasodilator originally developed as an oral antihypertensive. It is FDA-approved as a topical solution/foam for androgenetic alopecia and used off-label in low oral doses for hair loss.
Key Benefits
Slows or reverses androgenetic alopecia in men and women, prolongs anagen growth phase, increases hair shaft caliber, and (oral low-dose) helps cases unresponsive to topical formulations.
Mechanism of Action
Sulfated by sulfotransferase to active minoxidil sulfate, which opens ATP-sensitive potassium channels and dilates dermal microvasculature. Also stimulates dermal papilla VEGF expression, prolongs anagen phase, and shortens telogen.
Pharmacokinetics
▸ Application protocol Topical
- 1 Cleanse + dry skin. Pat skin dry; wait 15-20 min after washing for retinoids (reduces irritation). Skin must be fully dry — moisture amplifies penetration and irritation.
- 2 Pea-sized amount (or thin layer) for the entire treatment area. More is not better — irritation scales faster than efficacy.
- 3 Layering rules. Avoid combining with benzoyl peroxide (degrades retinoids), AHAs, or salicylic acid in the same routine. Niacinamide and ceramides are safe co-applications.
- 4 Sunscreen mandatory next AM. Most topicals (especially retinoids, hydroquinone) increase photosensitivity. SPF 30+ broad-spectrum minimum.
- 5 Ramp slowly. Start every-other-night for 2-4 weeks; increase to nightly only after tolerance builds. Skipping a night during peak irritation is the right move.
No systemic dosing required — topicals act locally with minimal serum absorption at standard doses.
Research Indications
Anagen prolongation
minoxidil sulfate extends the growth phase of the hair cycle, so individual hairs spend more time growing and reach greater terminal leng…
Follicle enlargement
miniaturized follicles in androgenetic alopecia partially re-thicken under chronic minoxidil; the size/diameter of the hair shaft increases.
Vascularization
dermal papilla blood flow increases — this was the original intuition (the drug is a vasodilator, more blood = more growth) but is now th…
Wnt/β-catenin signaling
minoxidil sulfate activates this pathway in dermal papilla cells in vitro, promoting anagen induction. Plausible mechanism but not fully …
Prostaglandin effects
some evidence minoxidil modulates prostaglandin synthesis at the follicle, though less central than for latanoprost-class compounds.
What it does NOT do
minoxidil does not affect DHT levels or androgen receptor signaling at all. It is mechanistically orthogonal to finasteride/dutasteride (…
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Standard MPB combo. Mechanistically distinct (DHT suppression + anagen prolongation), additive in trials. Canonical "Big 3" with ketoconazole shampoo.
Mechanistically distinct (AR blockade vs. anagen prolongation/vascularization), no PK interaction. Frequently stacked, often in same daily application (apply…
Modest independent effect on AGA (anti-inflammatory + minor antiandrogen); standard adjunct.
Co-applied to upregulate scalp SULT1A1 → rescues some non-responders. Increases skin irritation; usually 2-3×/week dosing.
Mechanically increases drug penetration + induces wound-healing growth signals. Several small RCTs show added benefit.
(ACE inhibitors, ARBs, calcium channel blockers, alpha-blockers): for oral LDOM specifically — additive hypotension risk. Topical use is fine.
(high-dose caffeine, ephedrine, oral phenylephrine — and amphetamines): theoretical concern with oral LDOM that the combination of vasodilation + sympathetic…
(legacy antihypertensive, rarely used now): severe hypotension when combined with oral minoxidil — explicit FDA label warning for Loniten.
Quality Indicators
Stable cream/serum base
Should have a uniform texture, no separation, no off odor.
Color drift
Some actives oxidize when exposed to air or light; minor color shift can be normal.
Separation or off smell
Phase separation, mold, or strong rancid odor indicates degraded product — discard.
What to Expect
- Week 1-2Application protocol established. Watch for irritation.
- Week 4Early visible/measurable change. Most topicals are slow.
- Week 8-12Meaningful effect window for most topical actives.
- Month 6+Maintenance phase. Stopping reverses gains over weeks-months.
Side Effects & Safety
Topical:
- Common (>10%):
- Initial telogen effluvium / shed at weeks 4-8 (cycle artifact, not toxicity)
- Scalp itch / dryness — usually propylene glycol related; foam version is PG-free
- Less common (1-10%):
- Allergic contact dermatitis (often to PG vehicle; switch to foam)
- Unwanted facial hair growth in women
- Mild systemic absorption symptoms — palpitations, headache, dizziness — at high application volume / damaged scalp barrier
- Rare-serious (<1%):
- Severe contact dermatitis requiring discontinuation
- Tachycardia / chest pain — discontinue if onset
- Pericardial effusion — extremely rare with topical, theoretical concern from oral mechanism
Oral LDOM (1.25-2.5 mg/day):
- Common (>10%):
- Hypertrichosis (facial, body hair growth) — universal, dose-dependent
- Mild ankle edema in some users
- Less common (1-10%):
- Palpitations / mild reflex tachycardia (often first 2-4 weeks)
- Hypotension / orthostatic dizziness — usually mild
- Headache
- Transient hair shed (cycle artifact, weeks 4-8)
- Rare-serious (<1% at LDOM doses):
- Pericardial effusion — well-documented at hypertensive doses (5-40 mg/day); rare at <2.5 mg/day but reported. Watch for unexplained chest pain, dyspnea, fatigue.
- Sustained reflex tachycardia requiring beta-blocker
- Significant fluid retention / lower extremity edema requiring diuretic
- Allergic reactions (rare)
- High-dose hypertension use only (5-40 mg/day, irrelevant to MPB):
- Pericardial effusion (3% rate in older hypertension trials)
- Heart failure precipitation in susceptible patients
- Stevens-Johnson syndrome (rare)
Specific watch periods:
- Weeks 1-4 (oral): Watch for tachycardia, edema, dizziness. Baseline BP/HR before starting; check at 2 weeks and 6 weeks.
- Weeks 4-8 (any route): Initial shed phase — don't panic-quit.
- Months 1-3 (oral): Edema and hair-growth pattern stabilize. Reduce dose or stop if unmanageable.
- Annually: BP/HR check, ankle edema check. If symptomatic, echocardiogram to rule out effusion.
References
Upjohn / Pfizer Rogaine 5% prescribing information
FDA OTC monograph for topical minoxidil
View StudyLoniten (oral minoxidil) prescribing information
FDA label, refractory hypertension dosing
View StudySinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone — Int J Dermatol 2018
early LDOM paper
View StudyVañó-Galván S et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients — JAAD 2021
largest LDOM safety dataset
View StudyOng MM, Li Y, Lipner SR. Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations — Am J Clin Dermatol 2026
synthesis review
View StudyJimenez-Cauhe J et al. Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review — J Clin Med 2025
adverse-event management
View StudyGodse K et al. Low-dose Oral Minoxidil in the Treatment of Alopecia: Evidence and Experience-based Consensus Statement of Indian Experts — Int J Trichology 2023
expert consensus
View StudyRamos PM et al. Female-pattern hair loss treated with low-dose oral minoxidil — Skin Appendage Disord 2020
LDOM efficacy in women
View StudyOlsen EA et al. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil — JAAD 1990
long-term topical efficacy
View StudyLucky AW et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss — JAAD 2004
dose comparison
View StudyGoren A et al. Clinical utility and validity of minoxidil response testing in androgenetic alopecia — Dermatol Ther 2015
SULT1A1 sulfation assay
View StudyBuhl AE et al. Minoxidil sulfate is the active metabolite that stimulates hair follicles — J Invest Dermatol 1990
sulfation as activation step
View StudyHu R, Xu F, Sheng Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia — Dermatol Ther 2015
combo evidence
View StudyGupta AK et al. Low-dose oral minoxidil for hair loss — meta-analysis review — JAAD 2022
synthesis of LDOM evidence as of 2022
View Studyr/tressless minoxidil megathread
community-curated dosing protocols and side-effect logs
View StudyLatest research
- reviewOral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations2026 Am J Clin Dermatol review (Ong, Li, Lipner) — synthesis of risks/benefits and dosing recommendations for LDOM across MPB, FPHL, and special populations.
- reviewCharacterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative ReviewJ Clin Med 2025 (Jimenez-Cauhe, Vaño-Galvan et al) — practical management of hypertrichosis, edema, palpitations, postural hypotension at LDOM doses; mitigation algorithms.
- retrospective-cohortEffectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service EvaluationCureus 2025 (Johnson et al) — combined LDOM + oral finasteride retrospective in male AGA confirms additive efficacy and acceptable tolerability.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.